PL3890781T3 - Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną - Google Patents

Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną

Info

Publication number
PL3890781T3
PL3890781T3 PL19820858.9T PL19820858T PL3890781T3 PL 3890781 T3 PL3890781 T3 PL 3890781T3 PL 19820858 T PL19820858 T PL 19820858T PL 3890781 T3 PL3890781 T3 PL 3890781T3
Authority
PL
Poland
Prior art keywords
combination
immune checkpoint
checkpoint inhibitor
sonodynamic therapy
sonodynamic
Prior art date
Application number
PL19820858.9T
Other languages
English (en)
Inventor
John Callan
Anthony Mchale
Original Assignee
Sonotarg Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonotarg Limited filed Critical Sonotarg Limited
Publication of PL3890781T3 publication Critical patent/PL3890781T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19820858.9T 2018-12-05 2019-12-05 Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną PL3890781T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1819853.1A GB201819853D0 (en) 2018-12-05 2018-12-05 Therapy
PCT/GB2019/053441 WO2020115491A2 (en) 2018-12-05 2019-12-05 Therapy

Publications (1)

Publication Number Publication Date
PL3890781T3 true PL3890781T3 (pl) 2026-03-23

Family

ID=65030185

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19820858.9T PL3890781T3 (pl) 2018-12-05 2019-12-05 Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną

Country Status (6)

Country Link
US (1) US20220062417A1 (pl)
EP (1) EP3890781B1 (pl)
ES (1) ES3057007T3 (pl)
GB (1) GB201819853D0 (pl)
PL (1) PL3890781T3 (pl)
WO (1) WO2020115491A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160243234A1 (en) 2013-09-27 2016-08-25 Phoenix Solutions As Ultrasound mediated delivery of drugs
JP2022521831A (ja) * 2019-03-29 2022-04-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 標的指向性協働的がん免疫療法
KR102379296B1 (ko) * 2019-09-02 2022-03-29 (주)아이엠지티 면역 마이크로버블 복합체 및 이의 이용
KR102578025B1 (ko) * 2020-12-07 2023-09-15 (주)아이엠지티 초음파 감작제가 결합된 면역관문억제제 및 이의 용도
GB2629999B (en) * 2021-04-21 2025-03-26 Act Therapeutics Ltd Enhancement of treatment with immunotherapeutic agents
CN114588268B (zh) * 2022-03-25 2023-05-26 清华大学 提高激活sting通路和抗肿瘤t细胞应答的方法
NO20221187A1 (en) 2022-11-04 2024-05-06 Exact Therapeutics As Method and system for calculating a point estimate of an ultrasound dose

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122444A1 (en) * 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
GB201106803D0 (en) * 2011-04-21 2011-06-01 Univ Ulster Sonodynamic therapy
US8748446B2 (en) 2012-03-03 2014-06-10 Nanoquantum Sciences, Inc. Halogenated compounds for photodynamic therapy
WO2015181343A2 (en) * 2014-05-30 2015-12-03 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for pd-l1
WO2016061256A1 (en) * 2014-10-14 2016-04-21 The University Of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
AU2016293674B2 (en) * 2015-07-16 2019-11-21 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
GB201520649D0 (en) 2015-11-23 2016-01-06 Univ Ulster Sonodynamic therapy
GB201708663D0 (en) * 2017-05-31 2017-07-12 Univ Ulster Therapy

Also Published As

Publication number Publication date
ES3057007T3 (en) 2026-02-25
GB201819853D0 (en) 2019-01-23
EP3890781C0 (en) 2025-10-08
EP3890781A2 (en) 2021-10-13
EP3890781B1 (en) 2025-10-08
US20220062417A1 (en) 2022-03-03
WO2020115491A2 (en) 2020-06-11
WO2020115491A3 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
IL286282A (en) Use of palinabolin in combination with immune checkpoint inhibitors
PL3890781T3 (pl) Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną
IL265274A (en) Combined treatment of antibody and checkpoint inhibitor
HUE043847T2 (hu) Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
HUE070659T2 (hu) KDM1A inhibitor és annak felhasználása terápiában
SG10202005298RA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
IL292219A (en) Immune modulatory il-2 factors in combination with immune checkpoint inhibitors
IL258500A (en) Combination therapy with glutaminase inhibitors and immuno-oncology agents
HUE065176T2 (hu) Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
ZA201804223B (en) Bromodomain and extra-terminal protein inhibitor combination therapy
IL284053A (en) New compounds and their use in therapy
SMT202200135T1 (it) Terapia di combinazione con un inibitore di proteine a bromodomini ed extraterminali
IL273092A (en) HDAC suppressor in combination with immune checkpoint modulators for cancer treatment
GB201507721D0 (en) Immunosuppressive agents and their use in therapy
GB201702160D0 (en) Inhibitors for use in therapy
PL3157548T3 (pl) Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
GB201615844D0 (en) Agents for use in therapy
GB2575123B (en) Improvements in fasteners
HK40033868A (en) Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy
GB201800136D0 (en) Improvements in fasteners
HK1262072A1 (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
AU2016903724A0 (en) Antibody and checkpoint inhibitor combination therapy
GB201617451D0 (en) Polypeptides for use in therapy
GB201506127D0 (en) Immune checkpoint inhibitor combinations